Recital 28, Regulation (EU) 2024/568

In forcesince 7 Feb 2024

Generic medicinal products for human use and generic veterinary medicinal products, medicinal products for human use and veterinary medicinal products authorised under the provisions relating to well-established medicinal use, homeopathic medicinal products for human use and homeopathic veterinary medicinal products, as well as herbal medicinal products for human use should be subject to a reduced annual pharmacovigilance fee, as those medicinal products generally have a well-established safety profile. However, in cases where such medicinal products are the subject of pharmacovigilance procedures at Union level, the full fee should be levied by the Agency in view of the additional work involved.